External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology APAO 2024
Roche and Genentech at

APAO 2024

February 22 - February 25
Bali, Indonesia
apao.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 30 / Roche
Change in treatment paradigm for DME and nAMD with faricimab▼ - Evidence from clinical trials and real-world practice
Targeting additional pathways beyond vascular endothelial growth factor A (VEGF-A) may address treatment challenges in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The Angiopoietin (Ang)-Tie pathway shows promise as a novel therapeutic target to address the vascular instability observed in retinal diseases such as DME and nAMD. In this symposium, 3 expert panellists will summarise the impact of dual Ang-2/VEGF-A inhibition, highlight opportunities to improve clinical outcomes in DME and nAMD, outline clinical trial evidence showing the potential benefits of dual Ang-2/VEGF-A inhibition, and review real-world patient cases.
Ophthalmology Diabetic Macular Edema Neovascular Age Related Macular Degeneration APAO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Apr 30 / Roche
Change in treatment paradigm for DME and nAMD with faricimab▼ - Evidence from clinical trials and real–world practice
Targeting additional pathways beyond vascular endothelial growth factor A (VEGF-A) may address treatment challenges in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The Angiopoietin (Ang)-Tie pathway shows promise as a novel therapeutic target to address the vascular instability observed in retinal diseases such as DME and nAMD. In this symposium, 3 expert panellists will summarise the impact of dual Ang-2/VEGF-A inhibition, highlight opportunities to improve clinical outcomes in DME and nAMD, outline clinical trial evidence showing the potential benefits of dual Ang-2/VEGF-A inhibition, and review real-world patient cases.
Ophthalmology Diabetic Macular Edema Neovascular Age Related Macular Degeneration APAO-2024

Sign up or login to unlock the full suite of MEDICALLY features
Feb 26 / Roche and Genentech
Faricimab▼ Treatment Outcomes With Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
This presentation describes personalized treat-and-extend–based (T&E) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab▼ in patients with diabetic macular edema. It presents a trial case study and images from patients who received faricimab▼ T&E, a regimen that allowed adjustable dosing up to every 16 weeks.
Ophthalmology Diabetic Macular Edema APAO-2024
03:00 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Faricimab▼ Treatment Outcomes With Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
Chang A, Lim J, Singer M, Idowu O, Hill L, Gibson K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:04 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Biomarkers for Vascular Stability Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition With Faricimab▼ in Phase 3 Trials in DME
Szeto S, Tan C, Maunz A, Patel K, von Schulthess E, Wang T, Willis J
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:08 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, Durability and Safety of Faricimab▼ in nAMD: 48-Week Results From the China Subpopulation of Phase 3 LUCERNE
Chen Y, Zhang M, Sun D, Li S, Patel S, Liu R
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:12 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Li X, Sun X, Jiang Q, Idowu O, Tang Y, Liu R
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:26 PM
duration 4mins Mengwi 1,2 (BNDCC 2-GF)
Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials
Tan A, Singer M, Hill L, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:08 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Results From the Portal 5-Year Subgroup Analysis
Hwang DK, Cheung G, Howard J, Nielsen J, Singh N, Cavichini Cordeiro M
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:32 PM
Duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR): Results From the Phase 3 Pagoda and Pavilion Trials
Sagong M, Emanuelli A, Holekamp N, Heinrich D, Pieramici D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:40 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Eyes With Neovascular Age-Related Macular Degeneration
Chaikitmongkol V, Khanani A, Margaron P, Souverain A, Patel S
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:44 PM
duration 4mins Mengwi 3,5 (BNDCC 2-GF)
Greater Reduction in Macular Leakage in DME With Faricimab▼ vs Aflibercept
Tan G, Goldberg R, Nudleman E, Sivaprasad S, Wang T, Mar F
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.